ATE467422T1 - Behandlung von aspergillus-infektionen mit thymosin alpha 1 - Google Patents

Behandlung von aspergillus-infektionen mit thymosin alpha 1

Info

Publication number: ATE467422T1
Authority: AT; Austria
Prior art keywords: thymosin alpha; treating; aspergillus infections; treating aspergillus; immuno
Prior art date: 2003-03-28

Application number

AT04749495T

Other languages

English (en)

Inventor

Guido Rasi

Enrico Garaci

Francesco Bistoni

Luigina Romani

Francesco Paolo Di

Original Assignee

Sciclone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-28

Filing date

2004-03-29

Publication date

2010-05-15

2004-03-29 Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc

2010-05-15 Application granted granted Critical

2010-05-15 Publication of ATE467422T1 publication Critical patent/ATE467422T1/de

Links

108010078233 Thymalfasin Proteins 0.000 title abstract 2
102400000800 Thymosin alpha-1 Human genes 0.000 title abstract 2
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 title abstract 2
229960004231 thymalfasin Drugs 0.000 title abstract 2
201000002909 Aspergillosis Diseases 0.000 title 1
208000036641 Aspergillus infections Diseases 0.000 title 1
241000228212 Aspergillus Species 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010061598 Immunodeficiency Diseases 0.000 abstract 1
230000003213 activating effect Effects 0.000 abstract 1
238000010322 bone marrow transplantation Methods 0.000 abstract 1
210000004443 dendritic cell Anatomy 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04749495T 2003-03-28 2004-03-29 Behandlung von aspergillus-infektionen mit thymosin alpha 1 ATE467422T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45791103P	2003-03-28	2003-03-28
PCT/US2004/009550 WO2004087067A2 (en)	2003-03-28	2004-03-29	Treatment of aspergillus infections with thymosin alpha 1

Publications (1)

Publication Number	Publication Date
ATE467422T1 true ATE467422T1 (de)	2010-05-15

Family

ID=42828702

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04749495T ATE467422T1 (de)	2003-03-28	2004-03-29	Behandlung von aspergillus-infektionen mit thymosin alpha 1

Country Status (17)

Country	Link
US (2)	US8207294B2 (de)
EP (1)	EP1613340B1 (de)
JP (1)	JP4629033B2 (de)
KR (1)	KR101089145B1 (de)
AT (1)	ATE467422T1 (de)
AU (1)	AU2004226403B2 (de)
BR (1)	BRPI0408892A (de)
CA (1)	CA2520400C (de)
DK (1)	DK1613340T3 (de)
EA (1)	EA008037B1 (de)
IL (1)	IL171118A (de)
MX (1)	MXPA05010391A (de)
NO (1)	NO329997B1 (de)
NZ (1)	NZ542900A (de)
PL (1)	PL1613340T3 (de)
UA (1)	UA80870C2 (de)
WO (1)	WO2004087067A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0408892A (pt)	2003-03-28	2006-04-11	Sciclone Pharmaceuticals Inc	uso de timosina alfa 1 para tratar as infecções por arpergillus
EA015510B1 (ru) *	2004-12-06	2011-08-30	Сциклон Фармасьютикалс, Инк.	Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация
BRPI0712595A2 (pt) *	2006-05-19	2012-07-03	Sigma Tau Ind Farmaceuti	uso de timosina alfa 1 para o tratamento de doenças imunológicas.
ITRM20060583A1 (it) *	2006-10-27	2008-04-28	Francesco Bistoni	Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie
WO2012109106A1 (en) *	2011-02-09	2012-08-16	Sciclone Pharmaceuticals, Inc.	Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
ITUB20153714A1 (it) *	2015-09-18	2017-03-18	Luigina Romani	Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica.
EP3865149A1 (de)	2015-02-09	2021-08-18	SciClone Pharmaceuticals International Ltd.	Thymosin-alpha 1 zur verwendung bei der behandlung von zystischer fibrose

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4002740A (en)	1975-08-21	1977-01-11	Gideon Goldstein	Tridecapeptide compositions and methods
US4079127A (en)	1976-10-28	1978-03-14	Board Of Regents Of The University Of Texas	Thymosin alpha 1
US4116951A (en)	1977-04-22	1978-09-26	Hoffmann-La Roche Inc.	[Asn2 ]-thymosin α1 and analogs thereof
DE2919592A1 (de)	1979-05-15	1981-01-15	Max Planck Gesellschaft	Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4612365A (en)	1980-03-25	1986-09-16	Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften	Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4374197A (en)	1980-10-30	1983-02-15	Hoffmann-La Rocche Inc.	Process for thymosin α1
TW224053B (de) *	1991-09-13	1994-05-21	Paul B Chretien
CN1058500C (zh)	1993-02-03	2000-11-15	施塞克龙药品公司	胸腺素α－1衍生物
CN1072961C (zh)	1993-03-05	2001-10-17	施塞克龙药品公司	治疗对干扰素治疗无反应者的丙型肝炎的方法
TW252045B (de) *	1993-10-07	1995-07-21	Allan L Goldstein
RU2107692C1 (ru) *	1995-06-07	1998-03-27	Дейгин Владислав Исакович	Пептид и способ его получения
US5888980A (en)	1994-06-30	1999-03-30	Bio-Logic Research And Development Corporation	Compositions for enhancing immune function
US5632983A (en)	1994-11-17	1997-05-27	University Of South Florida	Method for treating secondary immunodeficiency
WO1998035696A1 (en) *	1997-02-18	1998-08-20	Sciclone Pharmaceuticals, Inc.	Use of thymosin alpha 1 for the manufacture of a medicament for promoting stem cell development
UA80957C2 (en) *	2001-11-01	2007-11-26	Sciclone Pharmaceuticals Inc	Method of administering a thymosin alpha 1 peptide
BRPI0408892A (pt)	2003-03-28	2006-04-11	Sciclone Pharmaceuticals Inc	uso de timosina alfa 1 para tratar as infecções por arpergillus

2004
- 2004-03-29 BR BRPI0408892-1A patent/BRPI0408892A/pt not_active IP Right Cessation
- 2004-03-29 JP JP2006509423A patent/JP4629033B2/ja not_active Expired - Lifetime
- 2004-03-29 EA EA200501414A patent/EA008037B1/ru not_active IP Right Cessation
- 2004-03-29 WO PCT/US2004/009550 patent/WO2004087067A2/en not_active Ceased
- 2004-03-29 CA CA2520400A patent/CA2520400C/en not_active Expired - Lifetime
- 2004-03-29 US US10/551,341 patent/US8207294B2/en active Active
- 2004-03-29 UA UAA200509921A patent/UA80870C2/xx unknown
- 2004-03-29 AT AT04749495T patent/ATE467422T1/de active
- 2004-03-29 PL PL04749495T patent/PL1613340T3/pl unknown
- 2004-03-29 AU AU2004226403A patent/AU2004226403B2/en not_active Ceased
- 2004-03-29 DK DK04749495.0T patent/DK1613340T3/da active
- 2004-03-29 EP EP04749495A patent/EP1613340B1/de not_active Expired - Lifetime
- 2004-03-29 KR KR1020057018335A patent/KR101089145B1/ko not_active Expired - Fee Related
- 2004-03-29 MX MXPA05010391A patent/MXPA05010391A/es active IP Right Grant
- 2004-03-29 NZ NZ542900A patent/NZ542900A/en not_active IP Right Cessation
2005
- 2005-09-27 IL IL171118A patent/IL171118A/en not_active IP Right Cessation
- 2005-10-24 NO NO20054912A patent/NO329997B1/no not_active IP Right Cessation
2012
- 2012-05-29 US US13/482,978 patent/US8389680B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1613340A4 (de)	2009-07-01
NO329997B1 (no)	2011-02-07
KR101089145B1 (ko)	2011-12-02
JP4629033B2 (ja)	2011-02-09
NZ542900A (en)	2007-06-29
BRPI0408892A (pt)	2006-04-11
UA80870C2 (en)	2007-11-12
DK1613340T3 (da)	2010-08-30
EP1613340A2 (de)	2006-01-11
AU2004226403A1 (en)	2004-10-14
IL171118A (en)	2011-10-31
CA2520400A1 (en)	2004-10-14
EP1613340B1 (de)	2010-05-12
KR20050114264A (ko)	2005-12-05
EA200501414A1 (ru)	2006-04-28
US20120295840A1 (en)	2012-11-22
WO2004087067A2 (en)	2004-10-14
NO20054912D0 (no)	2005-10-24
JP2006521406A (ja)	2006-09-21
WO2004087067A3 (en)	2004-12-29
CA2520400C (en)	2013-02-19
US20070129292A1 (en)	2007-06-07
PL1613340T3 (pl)	2010-10-29
US8389680B2 (en)	2013-03-05
NO20054912L (no)	2005-12-20
EA008037B1 (ru)	2007-02-27
US8207294B2 (en)	2012-06-26
AU2004226403B2 (en)	2008-12-04
MXPA05010391A (es)	2005-11-04

Legal Events

Date

Code

Title

Description

2010-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1613340

Country of ref document: EP

Publication	Publication Date	Title
DE60026561D1 (de)	2006-05-04	Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
ATE404240T1 (de)	2008-08-15	Vorrichtung zur behandlung von biologischen geweben mittels elektrizität oder medikamenten
ATE539701T1 (de)	2012-01-15	Zusammengesetzte schlinge zur behandlung von inkontinenz
DE60045394D1 (de)	2011-01-27	Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
DE60119734D1 (de)	2006-06-22	Hpv-e7 zur behandlung von menschlichem papillomavirus
DE602005026294D1 (de)	2011-03-24	Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ATE292971T1 (de)	2005-04-15	(s,s)-reboxetin zur behandlung von peripheren neuropathien
ATE390142T1 (de)	2008-04-15	Synergistische zusammensetzung zur behandlung von diabetes mellitus
GB0518804D0 (en)	2005-10-26	Exudialysis tissue cleanser
EA200700965A1 (ru)	2007-10-26	Трегалоза и/или изомальтулоза в качестве носителя для сухой ароматической композиции
DE60045034D1 (de)	2010-11-11	Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
ATE531419T1 (de)	2011-11-15	Vorrichtung zur verabreichung von therapeutischen mitteln
DE60235545D1 (de)	2010-04-15	Verfahren zur behandlung von nagelpilz und anderen mikrobiellen und mykotischen erkrankungen und dafür geeignete zusammensetzungen
ATE427116T1 (de)	2009-04-15	Behandlung von bakteriellen infektionen
ATE427127T1 (de)	2009-04-15	Bioaktive beschichtung fur medizinische vorrichtung mit keratin
DK1778833T3 (da)	2011-06-27	Fremgangsmåder til anvendelse af regenerative celler til at fremme sårheling
ATE467422T1 (de)	2010-05-15	Behandlung von aspergillus-infektionen mit thymosin alpha 1
ATE516027T1 (de)	2011-07-15	Orazamid orotat zur vorbeugung von leberschäden
ATE372986T1 (de)	2007-09-15	N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridon s als antimikrobielle mittel
ATE372132T1 (de)	2007-09-15	Verfahren zum sterilisieren von gegenständen
DE60142899D1 (de)	2010-10-07	Verbindungen für den transfer von oligonukleotiden
TR200101841T2 (tr)	2001-12-21	Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
PT1237562E (pt)	2005-03-31	Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE60032915D1 (de)	2007-02-22	Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen
MXPA05004121A (es)	2006-02-17	Metodos para tratar la enfermedad de ojo reseco con lantibioticos.